Distribution of CGI-I score and CGI-S score at the last observation (FAS).
FAS, full analysis set; CGI-I, Clinical Global Impressions-Improvement. CGI-S, Clinical Global Impressions-Severity.MADRS response rate at the end of week 8 was achieved in 79.89%, 73.91%, and 42.39% in the ansofaxine 80 mg, 160 mg, and placebo groups, respectively. The difference reached a statistical significance for ansofaxine 80 mg/day group Patients in the ansofaxine 80 and 160 mg groups had a significantly higher HAM-DAt the end of the final evaluation, the changes of SDS total score from baseline were −8.3 ± 6.59, −8.2 ± 6.11, and −6.9 ± 6.05 in 80 mg, 160 mg and placebo groups, respectively (Table To understand how the MADRS anhedonia factor was influenced in this study, we did an additional analysis. Mean changes in MADRS anhedonia factor score from baseline to the end of week 8 were −6.66,−8, and −5.08 in the ansofaxine 80 mg, 160 mg, and placebo groups, respectively. A statistically significant decrease in LSM compared to placebo was observed in the ansofaxine 80 mg/day with a value of −1.58 [95% CI: (−2.24, −0.92), 